{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:04:47Z","timestamp":1791201887879,"version":"4.2.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2015,8,24]],"date-time":"2015-08-24T00:00:00Z","timestamp":1440374400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1038\/aps.2015.68","type":"journal-article","created":{"date-parts":[[2015,8,24]],"date-time":"2015-08-24T05:01:34Z","timestamp":1440392494000},"page":"1163-1169","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":116,"title":["Toward rapamycin analog (rapalog)-based precision cancer therapy"],"prefix":"10.1038","volume":"36","author":[{"given":"Ling-hua","family":"Meng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XF Steven","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,8,24]]},"reference":[{"key":"BFaps201568_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/nrm2672","volume":"10","author":"XM Ma","year":"2009","unstructured":"Ma XM, Blenis J . Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 2009; 10: 30\u201318.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"BFaps201568_CR2","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.cell.2009.03.046","volume":"137","author":"TR Peterson","year":"2009","unstructured":"Peterson TR, Laplante M, Thoreen CC, Sancak Y, Kang SA, Kuehl WM, et al. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 2009; 137: 873\u201386.","journal-title":"Cell"},{"key":"BFaps201568_CR3","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0092-8674(02)00833-4","volume":"110","author":"K Hara","year":"2002","unstructured":"Hara K, Maruki Y, Long XM, Yoshino K, Oshiro N, Hidayat S, et al. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 2002; 110: 177\u201389.","journal-title":"Cell"},{"key":"BFaps201568_CR4","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/j.cub.2004.06.054","volume":"14","author":"DD Sarbassov","year":"2004","unstructured":"Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004; 14: 1296\u2013302.","journal-title":"Curr Biol"},{"key":"BFaps201568_CR5","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa066838","volume":"356","author":"G Hudes","year":"2007","unstructured":"Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271\u201381.","journal-title":"N Engl J Med"},{"key":"BFaps201568_CR6","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","volume":"372","author":"RJ Motzer","year":"2008","unstructured":"Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449\u201356.","journal-title":"Lancet"},{"key":"BFaps201568_CR7","doi-asserted-by":"publisher","first-page":"4308","DOI":"10.1016\/j.bmcl.2010.05.099","volume":"20","author":"C Garcia-Echeverria","year":"2010","unstructured":"Garcia-Echeverria C . Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment. Bioorg Med Chem Lett 2010; 20: 4308\u201312.","journal-title":"Bioorg Med Chem Lett"},{"key":"BFaps201568_CR8","doi-asserted-by":"publisher","first-page":"594","DOI":"10.4161\/cc.11.3.19096","volume":"11","author":"Y Zhang","year":"2012","unstructured":"Zhang Y, Zheng XF . mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors. Cell cycle 2012; 11: 594\u2013603.","journal-title":"Cell cycle"},{"key":"BFaps201568_CR9","doi-asserted-by":"publisher","first-page":"24","DOI":"10.2174\/157488711793980147","volume":"6","author":"AS Don","year":"2011","unstructured":"Don AS, Zheng XF . Recent clinical trials of mTOR-targeted cancer therapies. Rev Recent Clin Trials 2011; 6: 24\u201335.","journal-title":"Rev Recent Clin Trials"},{"key":"BFaps201568_CR10","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1158\/1078-0432.CCR-13-0547","volume":"20","author":"JM Llovet","year":"2014","unstructured":"Llovet JM, Hernandez-Gea V . Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design. Clin Cancer Res 2014; 20: 2072\u20139.","journal-title":"Clin Cancer Res"},{"key":"BFaps201568_CR11","first-page":"21","volume":"347","author":"Y Samuels","year":"2010","unstructured":"Samuels Y, Waldman T . Oncogenic mutations of PIK3CA in human cancers. Curr Top Microbiol Immunol 2010; 347: 21\u201341.","journal-title":"Curr Top Microbiol Immunol"},{"key":"BFaps201568_CR12","doi-asserted-by":"publisher","first-page":"3222","DOI":"10.1038\/onc.2011.42","volume":"30","author":"B Weigelt","year":"2011","unstructured":"Weigelt B, Warne PH, Downward J . PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs. Oncogene 2011; 30: 3222\u201333.","journal-title":"Oncogene"},{"key":"BFaps201568_CR13","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1172\/JCI37539","volume":"120","author":"F Di Nicolantonio","year":"2010","unstructured":"Di Nicolantonio F, Arena S, Tabernero J, Grosso S, Molinari F, Macarulla T, et al. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest 2010; 120: 2858\u201366.","journal-title":"J Clin Invest"},{"key":"BFaps201568_CR14","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/cncr.28414","volume":"120","author":"HJ Mackay","year":"2014","unstructured":"Mackay HJ, Eisenhauer EA, Kamel-Reid S, Tsao M, Clarke B, Karakasis K, et al. Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer. Cancer 2014; 120: 603\u201310.","journal-title":"Cancer"},{"key":"BFaps201568_CR15","first-page":"5027","volume":"62","author":"Y Shi","year":"2002","unstructured":"Shi Y, Gera J, Hu L, Hsu JH, Bookstein R, Li W, et al. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res 2002; 62: 5027\u201334.","journal-title":"Cancer Res"},{"key":"BFaps201568_CR16","doi-asserted-by":"publisher","first-page":"7639","DOI":"10.1158\/0008-5472.CAN-06-0419","volume":"66","author":"HG Wendel","year":"2006","unstructured":"Wendel HG, Malina A, Zhao Z, Zender L, Kogan SC, Cordon-Cardo C, et al. Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo. Cancer Res 2006; 66: 7639\u201346.","journal-title":"Cancer Res"},{"key":"BFaps201568_CR17","doi-asserted-by":"publisher","first-page":"3993","DOI":"10.1158\/1078-0432.CCR-07-4152","volume":"14","author":"L Yang","year":"2008","unstructured":"Yang L, Clarke MJ, Carlson BL, Mladek AC, Schroeder MA, Decker P, et al. PTEN loss does not predict for response to RAD001 (Everolimus) in a glioblastoma orthotopic xenograft test panel. Clin Cancer Res 2008; 14: 3993\u20134001.","journal-title":"Clin Cancer Res"},{"key":"BFaps201568_CR18","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1093\/annonc\/mds057","volume":"23","author":"E Seront","year":"2012","unstructured":"Seront E, Rottey S, Sautois B, Kerger J, D'Hondt LA, Verschaeve V, et al. Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers. Ann Oncol 2012; 23: 2663\u201370.","journal-title":"Ann Oncol"},{"key":"BFaps201568_CR19","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1038\/bjc.2013.505","volume":"109","author":"E Seront","year":"2013","unstructured":"Seront E, Pinto A, Bouzin C, Bertrand L, Machiels JP, Feron O . PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K\/Akt activation. Br J Cancer 2013; 109: 1586\u201392.","journal-title":"Br J Cancer"},{"key":"BFaps201568_CR20","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1074\/jbc.M309999200","volume":"279","author":"JF Gera","year":"2004","unstructured":"Gera JF, Mellinghoff IK, Shi Y, Rettig MB, Tran C, Hsu JH, et al. AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem 2004; 279: 2737\u201346.","journal-title":"J Biol Chem"},{"key":"BFaps201568_CR21","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1158\/1078-0432.CCR-03-0043","volume":"10 (3)","author":"WC Noh","year":"2004","unstructured":"Noh WC, Mondesire WH, Peng J, Jian W, Zhang H, Dong J, et al. Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res 2004; 10 (3): 1013\u201323.","journal-title":"Clin Cancer Res"},{"key":"BFaps201568_CR22","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1158\/1078-0432.CCR-08-2166","volume":"15","author":"M Marinov","year":"2009","unstructured":"Marinov M, Ziogas A, Pardo OE, Tan LT, Dhillon T, Mauri FA, et al. AKT\/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001. Clin Cancer Res 2009; 15: 1277\u201387.","journal-title":"Clin Cancer Res"},{"key":"BFaps201568_CR23","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1038\/sj.onc.1210019","volume":"26","author":"P Frost","year":"2007","unstructured":"Frost P, Shi Y, Hoang B, Lichtenstein A . AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells. Oncogene 2007; 26: 2255\u201362.","journal-title":"Oncogene"},{"key":"BFaps201568_CR24","doi-asserted-by":"publisher","first-page":"379","DOI":"10.3816\/CGC.2007.n.020","volume":"5","author":"D Cho","year":"2007","unstructured":"Cho D, Signoretti S, Dabora S, Regan M, Seeley A, Mariotti M, et al. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 2007; 5: 379\u201385.","journal-title":"Clin Genitourin Cancer"},{"key":"BFaps201568_CR25","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1126\/science.1226344","volume":"338","author":"G Iyer","year":"2012","unstructured":"Iyer G, Hanrahan AJ, Milowsky MI, Al-Ahmadie H, Scott SN, Janakiraman M, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science 2012; 338: 221.","journal-title":"Science"},{"key":"BFaps201568_CR26","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1056\/NEJMoa1403352","volume":"371","author":"N Wagle","year":"2014","unstructured":"Wagle N, Grabiner BC, Van Allen EM, Amin-Mansour A, Taylor-Weiner A, Rosenberg M, et al. Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med 2014; 371: 1426\u201333.","journal-title":"N Engl J Med"},{"key":"BFaps201568_CR27","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.ccell.2014.09.008","volume":"26","author":"JD Thomas","year":"2014","unstructured":"Thomas JD, Zhang YJ, Wei YH, Cho JH, Morris LE, Wang HY, et al. Rab1A is an mTORC1 activator and a colorectal oncogene. Cancer cell 2014; 26: 754\u201369.","journal-title":"Cancer cell"},{"key":"BFaps201568_CR28","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1126\/science.1232044","volume":"340","author":"L Bar-Peled","year":"2013","unstructured":"Bar-Peled L, Chantranupong L, Cherniack AD, Chen WW, Ottina KA, Grabiner BC, et al. A Tumor suppressor complex with GAP activity for the Rag GTPases that signal amino acid sufficiency to mTORC1. Science 2013; 340: 1100\u20136.","journal-title":"Science"},{"key":"BFaps201568_CR29","doi-asserted-by":"publisher","first-page":"27531","DOI":"10.1074\/jbc.270.46.27531","volume":"270","author":"MC Lorenz","year":"1995","unstructured":"Lorenz MC, Heitman J . TOR mutations confer rapamycin resistance by preventing interaction with FKBP12-rapamycin. J Biol Chem 1995; 270: 27531\u20137.","journal-title":"J Biol Chem"},{"key":"BFaps201568_CR30","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1038\/onc.2010.28","volume":"29","author":"T Sato","year":"2010","unstructured":"Sato T, Nakashima A, Guo L, Coffman K, Tamanoi F . Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer. Oncogene 2010; 29: 2746\u201352.","journal-title":"Oncogene"},{"key":"BFaps201568_CR31","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1158\/2159-8290.CD-13-0929","volume":"4","author":"BC Grabiner","year":"2014","unstructured":"Grabiner BC, Nardi V, Birsoy K, Possemato R, Shen K, Sinha S, et al. A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity. Cancer Discov 2014; 4: 554\u201363.","journal-title":"Cancer Discov"},{"key":"BFaps201568_CR32","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1158\/2159-8290.CD-13-0353","volume":"4","author":"N Wagle","year":"2014","unstructured":"Wagle N, Grabiner BC, Van Allen EM, Hodis E, Jacobus S, Supko JG, et al. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov 2014; 4: 546\u201353.","journal-title":"Cancer Discov"},{"key":"BFaps201568_CR33","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.canlet.2006.11.008","volume":"251","author":"H Nozawa","year":"2007","unstructured":"Nozawa H, Watanabe T, Nagawa H . Phosphorylation of ribosomal p70 S6 kinase and rapamycin sensitivity in human colorectal cancer. Cancer Lett 2007; 251: 105\u201313.","journal-title":"Cancer Lett"},{"key":"BFaps201568_CR34","doi-asserted-by":"publisher","first-page":"5294","DOI":"10.1200\/JCO.2005.23.622","volume":"23","author":"E Galanis","year":"2005","unstructured":"Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, Ballman K, Boni J, et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 2005; 23: 5294\u2013304.","journal-title":"J Clin Oncol"},{"key":"BFaps201568_CR35","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/modpathol.3800995","volume":"21","author":"OH Iwenofu","year":"2008","unstructured":"Iwenofu OH, Lackman RD, Staddon AP, Goodwin DG, Haupt HM, Brooks JS . Phospho-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy. Mod Pathol 2008; 21: 231\u20137.","journal-title":"Mod Pathol"},{"key":"BFaps201568_CR36","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1002\/cncr.22195","volume":"107","author":"J Castellvi","year":"2006","unstructured":"Castellvi J, Garcia A, Rojo F, Ruiz-Marcellan C, Gil A, Baselga J, et al. Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer. Cancer 2006; 107: 1801\u201311.","journal-title":"Cancer"},{"key":"BFaps201568_CR37","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/s00432-008-0529-5","volume":"135","author":"S Darb-Esfahani","year":"2009","unstructured":"Darb-Esfahani S, Faggad A, Noske A, Weichert W, Buckendahl AC, Muller B, et al. Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to rapamycin treatment in vitro. J Cancer Res Clin Oncol 2009; 135: 933\u201341.","journal-title":"J Cancer Res Clin Oncol"},{"key":"BFaps201568_CR38","doi-asserted-by":"publisher","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","volume":"27","author":"G Hess","year":"2009","unstructured":"Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, Gisselbrecht C, et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009; 27: 3822\u20139.","journal-title":"J Clin Oncol"},{"key":"BFaps201568_CR39","doi-asserted-by":"publisher","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","volume":"23","author":"TE Witzig","year":"2005","unstructured":"Witzig TE, Geyer SM, Ghobrial I, Inwards DJ, Fonseca R, Kurtin P, et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005; 23: 5347\u201356.","journal-title":"J Clin Oncol"},{"key":"BFaps201568_CR40","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/nm1337","volume":"12","author":"GV Thomas","year":"2006","unstructured":"Thomas GV, Tran C, Mellinghoff IK, Welsbie DS, Chan E, Fueger B, et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 2006; 12: 122\u20137.","journal-title":"Nat Med"},{"key":"BFaps201568_CR41","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/nrclinonc.2010.42","volume":"7","author":"L Gossage","year":"2010","unstructured":"Gossage L, Eisen T . Alterations in VHL as potential biomarkers in renal-cell carcinoma. Nat Rev Clin Oncol 2010; 7: 277\u201388.","journal-title":"Nat Rev Clin Oncol"},{"key":"BFaps201568_CR42","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.1002\/cncr.24438","volume":"115","author":"RA Figlin","year":"2009","unstructured":"Figlin RA, de Souza P, McDermott D, Dutcher JP, Berkenblit A, Thiele A, et al. Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha. Cancer 2009; 115: 3651\u201360.","journal-title":"Cancer"},{"key":"BFaps201568_CR43","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s00109-010-0635-0","volume":"88","author":"G Chen","year":"2010","unstructured":"Chen G, Yang N, Wang X, Zheng SY, Chen Y, Tong LJ, et al. Identification of p27\/KIP1 expression level as a candidate biomarker of response to rapalogs therapy in human cancer. J Mol Med (Berl) 2010; 88: 941\u201352.","journal-title":"J Mol Med (Berl)"},{"key":"BFaps201568_CR44","doi-asserted-by":"crossref","first-page":"277","DOI":"10.18632\/oncotarget.859","volume":"4","author":"S Diersch","year":"2013","unstructured":"Diersch S, Wenzel P, Szameitat M, Eser P, Paul MC, Seidler B, et al. Efemp1 and p27(Kip1) modulate responsiveness of pancreatic cancer cells towards a dual PI3K\/mTOR inhibitor in preclinical models. Oncotarget 2013; 4: 277\u201388.","journal-title":"Oncotarget"},{"key":"BFaps201568_CR45","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/gm174","volume":"2","author":"C Swanton","year":"2010","unstructured":"Swanton C, Larkin JM, Gerlinger M, Eklund AC, Howell M, Stamp G, et al. Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets. Genome Med 2010; 2: 53.","journal-title":"Genome Med"},{"key":"BFaps201568_CR46","doi-asserted-by":"publisher","first-page":"17414","DOI":"10.1073\/pnas.0809136105","volume":"105","author":"AY Choo","year":"2008","unstructured":"Choo AY, Yoon SO, Kim SG, Roux PP, Blenis J . Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci U S A 2008; 105: 17414\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"BFaps201568_CR47","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","volume":"66","author":"KE O'Reilly","year":"2006","unstructured":"O'Reilly KE, Rojo F, She Q-B, Solit D, Mills GB, Smith D, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006; 66: 1500\u20138.","journal-title":"Cancer Res"},{"key":"BFaps201568_CR48","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1042\/BST0370217","volume":"37","author":"J Huang","year":"2009","unstructured":"Huang J, Manning BD . A complex interplay between Akt, TSC2, and the two mTOR complexes. Biochem Soc Trans 2009; 37: 217.","journal-title":"Biochem Soc Trans"},{"key":"BFaps201568_CR49","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2174\/157489210789702208","volume":"5","author":"SE Ghayad","year":"2010","unstructured":"Ghayad SE, Cohen PA . Inhibitors of the PI3K\/Akt\/mTOR pathway: new hope for breast cancer patients. Recent Pat Anticancer Drug Discov 2010; 5: 29\u201357.","journal-title":"Recent Pat Anticancer Drug Discov"},{"key":"BFaps201568_CR50","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.1158\/1535-7163.MCT-06-0166","volume":"5","author":"E Buck","year":"2006","unstructured":"Buck E, Eyzaguirre A, Brown E, Petti F, McCormack S, Haley JD, et al. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol Cancer Ther 2006; 5: 2676\u201384.","journal-title":"Mol Cancer Ther"},{"key":"BFaps201568_CR51","doi-asserted-by":"publisher","first-page":"R32","DOI":"10.1186\/bcr3724","volume":"16","author":"J Singh","year":"2014","unstructured":"Singh J, Novik Y, Stein S, Volm M, Meyers M, Smith J, et al. Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer. Breast Cancer Res 2014; 16: R32.","journal-title":"Breast Cancer Res"},{"key":"BFaps201568_CR52","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/S1470-2045(14)70138-X","volume":"15","author":"F Andre","year":"2014","unstructured":"Andre F, O'Regan R, Ozguroglu M, Toi M, Xu B, Jerusalem G, et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 2014; 15: 580\u201391.","journal-title":"Lancet Oncol"},{"key":"BFaps201568_CR53","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1200\/JCO.2014.56.2082","volume":"33","author":"TJ Hobday","year":"2015","unstructured":"Hobday TJ, Qin R, Reidy-Lagunes D, Moore MJ, Strosberg J, Kaubisch A, et al. Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors. J Clin Oncol 2015; 33:1551\u20136.","journal-title":"J Clin Oncol"},{"key":"BFaps201568_CR54","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1002\/cncr.24863","volume":"116","author":"H Huynh","year":"2010","unstructured":"Huynh H . AZD6244 (ARRY-142886) enhances the antitumor activity of rapamycin in mouse models of human hepatocellular carcinoma. Cancer 2010; 116: 1315\u201325.","journal-title":"Cancer"},{"key":"BFaps201568_CR55","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1093\/annonc\/mdu482","volume":"26","author":"AW Tolcher","year":"2015","unstructured":"Tolcher AW, Bendell JC, Papadopoulos KP, Burris HA, 3rd, Patnaik A, Jones SF, et al. A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors. Ann Oncol 2015; 26: 58\u201364.","journal-title":"Ann Oncol"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/aps201568.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/aps201568","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/aps201568.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T08:33:26Z","timestamp":1684398806000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/aps201568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,24]]},"references-count":55,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["BFaps201568"],"URL":"https:\/\/doi.org\/10.1038\/aps.2015.68","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,24]]},"assertion":[{"value":"14 April 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}